Aytu BioScience Inc. (AYTU)

What You Need to Know

Aytu BioScience is pursuing an emergency use authorization with the FDA for the COVID-19 IgG/IgM test. The COVID-19 IgG/IgM is a rapid test intended for the presumptive qualitative detection of IgG/IgM antibodies from the 2019-nCoV in blood samples from individuals with signs and symptoms of infection who are suspected of Sars Cov-2.

How can I stay informed about the availability of the COVID-19 IgG/IgM test?

Healthcare professionals, institutions, and other interested parties with questions about the Company’s recently licensed COVID-19 IgG/IgM Rapid Test are asked to send email inquiries to COVID-19@aytubio.com
_________________________________________________________________________________________________________________________________________________________________________

On Dec 9, 2020 AYTU effected a 1-for-10 REVERSE STOCK SPLIT (shares were trading at approx 60 cents pre-split in early Dec 2020 and then began trading at approx $6 per share post the reverse split being impletmented on Dec 9th, 2020):

On Dec 10th, 2020 AYTU released PR describing another "proposed merger" - this time with a company called "Neos Therapeutics " :

Almost as fast as that merger was announced - it was met with PR by a law firm indicating a possible lawsuit to block said merger:

On Dec 11th, 2020 almost immediately after completing a 1-for-10 reverse split, AYTU then released another PR indicating an additional dilutive share sale.  

This appears to be a repeating pattern with AYTU whereby their common shares get diluted down/fall below the NASDAQ minimum pricing requirements of $1 per share - at which point AYTU Sr Mgt (Josh Disbrow CEO) then reverse splits the stock, then almost immediately always follows with a dilutive sale of shares, called a "cash raise for working cash purposes".  Wash, rinse, repeat on a regular basis is the history of this stock and company: